Edge­wise Ther­a­peu­tics has shared plans to ad­vance its drug can­di­date for a ge­net­ic heart dis­ease in­to a reg­is­tra­tional study on the back of up­dat­ed Phase 2...

Plus, news about Mer­ck, Mul­ti­Va­lent Bio­ther­a­pies, Alvotech, en­Gene, Mirum, and Adap­tive Biotech­nolo­gies.

💸 Eli Lil­ly ac­quires an­oth­er pain biotech: The In­di­anapo­lis phar­ma gi­ant has made...

Glioblas­toma is no­to­ri­ous­ly good at evad­ing the im­mune sys­tem, mak­ing it par­tic­u­lar­ly re­sis­tant to im­munother­a­py, but now re­searchers may have found a clever workaround.

Sci­en­tists at...

PHILADEL­PHIA– Fol­low­ing the re­cent de­par­tures of FDA Com­mis­sion­er Mar­ty Makary and both of his cen­ter di­rec­tors for drugs and bi­o­log­ics, the Trump ad­min­is­tra­tion will...

With a for­mi­da­ble new com­peti­tor set to en­ter the orex­in de­vel­op­ment race, Take­da is out with new da­ta that it hopes will re­in­force mar­ket-lead­ing po­ten­tial...

CMS has pro­posed a pol­i­cy change that clar­i­fies its stance on how prod­ucts are grouped to­geth­er for Medicare ne­go­ti­a­tions.

Un­der the In­fla­tion Re­duc­tion Act, bi­o­log­ics...